#China #Chengdu #SHINE Technologies #C-Ray Therapeutics #Lu-177

Strategic Partnership for Lu-177 Distribution

In a significant move to enhance cancer treatment accessibility in China, SHINE Technologies, LLC has officially entered into a supply agreement with C-Ray Therapeutics located in Chengdu. This partnership marks C-Ray as the exclusive distributor of non-carrier-added lutetium-177 (n.c.a. Lu-177) throughout mainland China, aside from specific existing alliances of SHINE.

The Importance of Lu-177 in Cancer Therapy

Lu-177 is emerging as a cornerstone isotope in targeted radiopharmaceutical therapy, utilized in treatments for prostate cancer, neuroendocrine tumors, and other oncology-related conditions. Its vital attributes, such as a favorable half-life and the ability to co-image, make it one of the most relied upon therapeutic radioisotopes currently. The critical challenge faced by the Chinese market has always been supply security, which the collaboration aims to resolve.

Under this new agreement, C-Ray will supply SHINE's n.c.a. Lu-177 to various Chinese radiopharmaceutical innovators, biotechnology firms, and health institutions. The company will leverage its expansive 28,000-square-meter facility in Chengdu to provide comprehensive services, including isotope conjugation and quality control. This ensures that domestic companies can access high-quality radioisotope supplies and meet internationally established benchmarks.

Overcoming Supply Challenges

A longstanding hurdle for pipeline development in China has been reliable access to isotopes. Fortunately, SHINE's Cassiopeia facility, one of the largest production sites for n.c.a. Lu-177 in North America, will fulfill C-Ray's supply needs under terms that comply with both Chinese and U.S. regulations. C-Ray's local infrastructure further guarantees dependable delivery to clients across the region.

Additionally, SHINE is poised to assist Chinese developers in navigating the regulatory requirements of the National Medical Products Administration (NMPA), ensuring smooth integration and compliance for new therapies into the market.

Enhancing the Oncology Landscape in China

C-Ray Therapeutics’ General Manager, Haitao Qiao, emphasized that this partnership is a remarkable stride towards diversifying their supply. The stable access to multiple sources of isotopes enhances the consistent flow of supplies for their clients, bolstering operational resilience in the competitive field of radiopharmaceuticals.

"Our leadership in Ac-225 supply serves to further amplify the significance of securing a high-quality n.c.a. Lu-177 source with exclusive distribution rights. This will directly improve pipeline continuity and support the establishment of a robust radiopharmaceutical ecosystem in China," Qiao stated.

In a similar vein, SHINE's Founder and CEO, Greg Piefer, expressed optimism about the partnership as it addresses the rising demand for n.c.a. Lu-177. He noted how this collaboration will not only uphold strong supplies for existing clients in the U.S. and other global markets but also facilitate ground-breaking innovations in pipeline development.

About the Stakeholders

C-Ray Therapeutics

C-Ray Therapeutics is a leading CRDMO specializing in radiopharmaceutical development, offering a complete suite of services—from initial target validation all the way to commercial-scale GMP manufacturing. The Chengdu facility operates under China's strict Class A Radiation Safety License and has a broad portfolio of over 30 radioisotopes across various developmental stages.

SHINE Technologies

Based in Janesville, Wisconsin, SHINE is recognized for transforming the landscape of fusion technologies. The company has pioneered the production of medical isotopes essential for diagnostics and treatment, all while aiming to redefine energy creation through innovative fusion energy solutions. SHINE is committed to supporting sustainable energy endeavors and enhancing healthcare outcomes through its established practices.

Conclusion

This alliance between SHINE Technologies and C-Ray Therapeutics promises to fill the supply gap for Lu-177 in one of the world's fastest-expanding oncology markets. As both companies move forward, they stand firm in their mission to advance medical treatments and ensure patients have access to vital therapies. In doing so, this partnership not only enhances the prospects for cancer treatments in China but also sets an industry benchmark for radiopharmaceutical collaborations worldwide.